Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

Lin, Hui-Ming; Castillo, Lesley; Mahon, Kate; Chiam, Karen; Lee, Brian Y.; Nguyen, Quoc; Boyer, Michael; Stockler, Martin R.; Pavlakis, Nick; Marx, Gavin; Mallesara, Girish; Gurney, Howard; Clark, Susan J.; Swarbrick, Alexander; Daly, Roger J.; Horvath, Lisa G.

doi:10.1038/bjc.2014.181

Cited by 128 publications

(144 citation statements)

References 37 publications

(64 reference statements)

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…A total of 2,534 patients from the United Kingdom, Germany, Spain, Poland, Japan, Sweden, Korea, Norway, Denmark, Italy, USA, China and Chinese Taiwan were diagnosed with a variety of cancers, including esophageal cancer [12,19,27], gastric cancer [16,25,28], colorectal cancer [8,20,29], rectal cancer [30], hepatocellular carcinoma [26], pancreatic cancer [11], lung cancer [13], breast cancer [15], diffuse large B-cell lymphoma (DLBCL) [18], bladder cancer [10], endometrial cancer [14,17], ovarian cancer [9,21,23,24] and prostate cancer[22]. In the primary reports, 11 studies showed a significant association between high miR-200c and poor prognosis [8,9,13,15,16,17,18,19,20,21,22], 9 provided the opposite result [10,11,24,25,26,27,29,30] and 5 found no prognostic value of miR-200c for tumor patients [12,14,20,23,28]. The expression of miR-200c was most often detected in tumor tissue samples, while five studies tested it in plasma or serum [15,16,19,20,27].…”

Section: Resultsmentioning

confidence: 99%

“…So 18 studies were identified in the 16 articles and were enrolled into the meta-analysis (Fig. 1) [10,11,12,13,14,15,16,17,19,20,22,24,25,27,28,29]. It has been previously reported that there was no association between serum miR-200c and miR-200c in primary tumor tissue [20], thus we performed a meta-analysis based on both tissue and circulating miR-200c independently.…”

Section: Resultsmentioning

confidence: 99%

“…A total of six studies encompassing 723 tumor patients focused on blood miR-200c expression and the prognosis of patients [15,16,19,20,22,27]. All the HRs and corresponding 95% CIs are shown in Table 4.…”

Section: Resultsmentioning

confidence: 99%

“…All the HRs and corresponding 95% CIs are shown in Table 4. Five of six studies reported OS and displayed significant heterogeneity among them ( P <0.001, I 2 = 82.6%) (Table 3) [15,16,20,22,27]. Therefore, a random model was applied to overall data integration, and we found that patients with high miR-200c levels in blood had a significantly poorer OS (HR=3.07, 95% CI 1.58-5.96; P =0.001) (Table 3; Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Since 2006 [8], multiple studies have demonstrated the prognostic value of miR-200c in different cancers, including serous ovarian cancer [9], bladder cancer [10], pancreatic cancer [11], esophageal cancers [12], lung cancer [13] and endometrial cancer [14]. Nearly half of these studies revealed a significant association between miR-200c overexpression and poor prognosis [8,9,13,15,16,17,18,19,20,21,22]. However, other studies reported an insignificant association or opposite conclusions [10,11,12,14,23,24,25,26,27,28,29,30].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Prognostic Role of Tissue and Circulating MicroRNA-200c in Malignant Tumors: a Systematic Review and Meta-Analysis

Shao¹,

Geng²,

Gu³

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: Recently, many studies have shown that microRNAs (miRNA) exhibit altered expression in various cancers and may serve as prognostic biomarkers. We performed a systematic review and meta-analysis to evaluate the prognostic role of miR-200c expression in different cancers. Methods: Studies were recruited by searching PubMed, Embase and the Cochrane Library (last search update was May 2014) and assessed by further quality evaluation. Results: A total of 25 studies dealing with various carcinomas were identified for systematic review. Among them, 18 studies were ultimately included in the meta-analysis. Our results indicated that the expression of tissue miR-200c was not associated with OS and PFS in various carcinomas; however, downregulation of tissue miR-200c did predict poor OS of patients with stage I disease (HR=0.41, 95% CI 0.25-0.68, P=0.001). Furthermore, overexpression of blood miR-200c was significantly related to poor OS and PFS (HR=3.07 95% CI 1.58-5.96 P=0.001, HR=2.26 95% CI 1.66-3.08 P<0.001, respectively), especially in patients with advanced disease. Conclusion: This systematic review and meta-analysis clarified that low expression of miR-200c in primary tissue was significantly associated with poor survival in cancer patients at early stage, whereas a high level of blood miR-200c predicted poor prognosis in patients with advanced tumors.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Role of Tissue and Circulating MicroRNA-200c in Malignant Tumors: a Systematic Review and Meta-Analysis

Shao¹,

Geng²,

Gu³

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

Epigenetics as a Key Factor in Prostate Cancer

Enikeeva,

Rafikova,

Sharifyanova

et al. 2024

Advanced Biology

View full text Add to dashboard Cite

Nowadays, prostate cancer is one of the most common forms of malignant neoplasms in men all over the world. Against the background of increasing incidence, there is a high mortality rate from prostate cancer, which is associated with an inadequate treatment strategy. Such a high prevalence of prostate cancer requires the development of methods that can ensure early detection of the disease, improve the effectiveness of treatment, and predict the therapeutic effect. Under these circumstances, it becomes crucial to focus on the development of effective diagnostic and therapeutic approaches. Due to the development of molecular genetic methods, a large number of studies have been accumulated on the role of epigenetic regulation of gene activity in cancer development, since it is epigenetic changes that can be detected at the earliest stages of cancer development. The presence of epigenetic aberrations in tumor tissue and correlations with drug resistance suggest new therapeutic approaches. Detection of epigenetic alterations such as CpG island methylation, histone modification, and microRNAs as biomarkers will improve the diagnosis of the disease, and the use of these strategies as targets for therapy will allow for greater personalization of prostate cancer treatment.

show abstract

Circulating tumor cells in prostate cancer: Does (nuclear) size matter?

Pal

Agarwal

Jones

2015

Cancer

View full text Add to dashboard Cite

In the lay press, the terms "circulating tumor cell" (CTC) and "liquid biopsy" are often uttered in the same breath. Currently, however, the role of CTCs in clinical practice is solely as a prognostic tool as opposed to an aid in diagnosis or the personalization of therapy. In patients with prostate cancer, a correlation has been observed between baseline CTC enumeration and overall survival (OS) in a large cohort of men with castration-resistant prostate cancer (CRPC) who are receiving chemotherapy.1 More recently, a similar correlation with OS has been observed in men with metastatic CRPC treated on COU-AA-301, a pivotal phase 3 trial comparing abiraterone and prednisone in this population.2 As noted, these studies (both of which use the conventional CellSearch platform [Janssen Diagnostics, Raritan, NJ]) support the prognostic value of CTC enumeration; however, what remains elusive is a means of using this biomarker for treatment allocation.Although the study by Chen et al in this issue of Cancer does not definitively address this problem either, it does provide key insights into the role of CTCs in identifying unique subpopulations of prostate cancer.3 In their study, 57 men with varying stages of prostate cancer submitted a total of 148 blood samples. The NanoVelcro Chips system was used to isolate cells that were 4',6-diamidino-2-phenylindole (DAPI) positive/cytokeratin (CK) positive/CD45 negative, and isolated cells were assessed at high magnification (3100 or 3400) for nuclear size. Visually, these cells appear to have greater clarity and resolution than those typically identified with the CellSearch platform. Nuclear size was measured and trichotomized into large nuclear CTC, small nuclear CTC (snCTC), and very small nuclear CTC (vsnCTC) categories. Two key observations were noted. First, snCTCs and vsnCTCs were more frequent in patients with metastatic disease compared with patients with localized disease. Second, vsnCTCs were more frequent in patients with visceral metastatic disease (eg, lesions in the lungs or liver) compared with those with bone-only or lymph node-only metastases.The methods used to characterize CTCs in this experience also warrant a second look. A recent report from Ferraldeschi et al used the Epic Sciences platform (Epic Sciences Inc, La Jolla, Calif) to compare samples derived from 39 patients with metastatic CRPC with those from 10 healthy volunteers. 4 Of the 39 patients, 36 (92%) had CTCs detected that were CK negative, and among these, multiple patients had snCTCs identified. Thus, because the examination was limited to CK-positive events, the sensitivity of the current study by Chen et al could be limited.The findings of Chen et al's study are tempered by the limited sample size, which was divided further into subcategories based on clinical status. For example, the comparison of visceral versus nonvisceral metastases was predicated on a comparison of 21 and 13 patients, respectively.3 Furthermore, little description was offered related to the extent of prior therapy. It wa...

show abstract

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

Cited by 128 publications

References 37 publications

Prognostic Role of Tissue and Circulating MicroRNA-200c in Malignant Tumors: a Systematic Review and Meta-Analysis

Prognostic Role of Tissue and Circulating MicroRNA-200c in Malignant Tumors: a Systematic Review and Meta-Analysis

Epigenetics as a Key Factor in Prostate Cancer

Circulating tumor cells in prostate cancer: Does (nuclear) size matter?

Contact Info

Product

Resources

About